Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background: Atopic dermatitis (AD) is characterized by abnormal skin lipids that are largely driven by hyperactivated type 2 immune responses. The antibody to the α‐subunit of interleukin (IL)‐4 receptor, dupilumab, was recently approved to treat AD and demonstrated strong efficacy. However, the role of dupilumab therapy in the regulation of skin barrier structure and function has not been fully explored. Methods: We have evaluated the content of lipids and transepidermal water loss (TEWL) in lesional and non‐lesional skin of adults and adolescents with moderate‐to‐severe AD over the course of 16‐week treatment with dupilumab and compared those values with that of matched healthy volunteers. Results: Dupilumab treatment provided a significant decrease in TEWL in AD lesions, lowering it almost to the levels seen in the skin of healthy subjects. Blocking IL‐4/IL‐13 signaling with dupilumab normalized lipid composition (decreased levels of ceramides with non‐hydroxy fatty acids and C18‐sphingosine and increased the level of esterified omega‐hydroxy fatty acid‐containing ceramides) and increased ceramide chain length in lesional as well as non‐lesional stratum corneum of AD patients. Partial changes for these parameters were already observed after 2 weeks, with a full response achieved after 8 weeks of dupilumab treatment. Conclusions: Inhibition of IL‐4/IL‐13 signaling by dupilumab allows restoration of skin lipid composition and barrier function in patients with moderate‐to‐severe AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
The cornified envelope: a model of cell death in the skin
Candi, E., Schmidt, R., & Melino, G. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1619 · Cited by 1,776
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Filaggrin Mutations Associated with Skin and Allergic Diseases
Irvine, A. D., McLean, W. H. I., & Leung, D. Y. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011040 · Cited by 1,217
Self-citationAtopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Janssens, M., van Smeden, J., Gooris, G. S., Bras, W., Portale, G., Caspers, P. J., Vreeken, R. J., Hankemeier, T., Kezic, S., Wolterbeek, R., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p030338 · Cited by 488
van Smeden, J., & Bouwstra, J. A. (2016) · Current Problems in Dermatology · doi:10.1159/000441540 · Cited by 366
Kezic, S., O’Regan, G. M., Yau, N., Sandilands, A., Chen, H., Campbell, L. E., Kroboth, K., Watson, R., Rowland, M., Irwin McLean, W. H., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02540.x · Cited by 295
Lipid abnormalities in atopic skin are driven by type 2 cytokines
Berdyshev, E., Goleva, E., Bronova, I., Dyjack, N., Rios, C., Jung, J., Taylor, P., Jeong, M., Hall, C. F., Richers, B. N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98006 · Cited by 283
Self-citationEpithelial barrier repair and prevention of allergy
Goleva, E., Berdyshev, E., & Leung, D. Y. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124608 · Cited by 251
Self-citationThe nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype
Leung, D. Y. M., Calatroni, A., Zaramela, L. S., LeBeau, P. K., Dyjack, N., Brar, K., David, G., Johnson, K., Leung, S., Ramirez-Gama, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav2685 · Cited by 214
Self-citationt’Kindt, R., Jorge, L., Dumont, E., Couturon, P., David, F., Sandra, P., & Sandra, K. (2012) · Analytical Chemistry · doi:10.1021/ac202646v · Cited by 202
Cutaneous barrier dysfunction in allergic diseases
Leung, D. Y. M., Berdyshev, E., & Goleva, E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.02.021 · Cited by 190
Self-citationLipid abnormalities and lipid-based repair strategies in atopic dermatitis
Elias, P. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.10.001 · Cited by 78
Very long chain fatty acid-containing lipids: A decade of novel insights from the study of ELOVL4.
Yeboah, G. K., Lobanova, E. S., Brush, R. S., & Agbaga, M.-P. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100030 · Cited by 69
Cited by
Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier
You, H., & Liang, Y. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09057-y · Cited by 17
Langley, R. G., Gherardi, G., Coleman, A., Ardeleanu, M., Rodríguez-Marco, A., Levy, S., Bansal, A., Chen, Z., Rossi, A. B., Shumel, B., et al. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00952-w · Cited by 18
Self-citationAndrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
“It is used in patients with moderate to severe atopic dermatitis and has a favourable safety profile, confirmed by numerous clinical trials [38,115–122].”
Metadata
- Authors
- Berdyshev, E., Goleva, E., Bissonnette, R., Bronova, I., Bronoff, A. S., Richers, B. N., Garcia, S., Ramirez‐Gama, M., Taylor, P., Praestgaard, A., Agueusop, I., Jurvilliers, P., Boguniewicz, M., Levit, N. A., Rossi, A. B., Zhang, A., & Leung, D. Y. M.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2022-07-21
- Volume
- 77
- Issue
- 11
- Pages
- 3388-3397
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W4285043297
- Cited by
- 116
- References
- 16
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.